THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.15] ID: TIP-MED-000247 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Mifepristone (Antiprogestogen — Medical Termination Combi-Pack)

Active Ingredient / Scientific Identity: Mifepristone • Class: Synthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progesterone Receptor Antagonist)

⚖️ Compare Profile
Generic / Entity NameMifepristone (Antiprogestogen — Medical Termination Combi-Pack) ([12.15])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSynthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progesterone Receptor Antagonist
Available Dosage FormsTablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Mifepristone (Antiprogestogen — Medical Termination Combi-Pack) (TIP-MED-000247, Reference Code [12.15]) is classified under Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Synthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progesterone Receptor Antagonist). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.15], p. 162): Mifegest, Mifeprex, Unwanted-Kit (Combi-pack with Misoprostol) — Strengths & Dosage Forms: Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.15], p. 162): Mifegest, Mifeprex, Unwanted-Kit (Combi-pack with Misoprostol) — Strengths & Dosage Forms: Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
Dosage Forms & Available Strengths:
Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Competitively blocks endometrial and myometrial progesterone receptors -> causes decidual necrosis, detachment of conceptus, cervical softening, and sensitization of myometrium to prostaglandins.

4. Therapeutic Indications & Evidence-Supported Uses

  • Medical termination of intrauterine pregnancy (in sequential combination with Misoprostol under the MTP Act)
  • medical management of early fetal demise
  • cervical preparation prior to surgical abortion

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: Medical Termination (per MTP Rules / FOGSI guidelines): 200 mg PO single dose on Day 1 under medical supervision, followed 24-48 hours later by Misoprostol 800 mcg (four 200 mcg tablets) buccally/sublingually/vaginally. • Paediatric: Adolescent obstetric care under MTP Act provisions only.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
Elimination & Renal Adjustment:
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
Hepatic Impairment Considerations:
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (Mifepristone does NOT terminate ectopic pregnancy—rupture can be fatal); chronic adrenal failure; inherited porphyria; uncontrolled severe asthma; severe anaemia (Hb <7-8 g/dL) without transfusion access; IUD in situ (must be removed first). • Precautions: MANDATORY INDIAN STATUTORY COMPLIANCE (MTP Amendment Act 2021 & CDSCO Directives): Over-the-counter sale without a qualified Gynaecologist/MTP-certified RMP prescription is strictly illegal; ultrasound/clinical confirmation of intrauterine pregnancy and Rh-typing (Anti-D immunoglobulin within 72h if Rh-negative) are mandatory.

Key Clinical Precautions: Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Uterine cramping, prolonged vaginal spotting/bleeding (9-16 days), nausea, vomiting, dizziness.
  • Haemorrhage requiring transfusion or suction evacuation (1-3%), ruptured unrecognised ectopic pregnancy, Clostridium sordellii toxic shock sepsis (rare—presents as afebrile malaise, haemoconcentration, severe leukocytosis).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CYP3A4 inhibitors (Ketoconazole, Itraconazole, Erythromycin, Grapefruit juice) -> increase mifepristone levels; CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine) -> reduce efficacy and cause failed abortion; Corticosteroids (Dexamethasone) -> antiglucocorticoid effect reduces steroid efficacy for 3-4 days

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Take Day-1 tablet (Mifepristone 200 mg) first, then the 4 smaller tablets (Misoprostol) 24-48 hours later as instructed; return immediately for severe abdominal pain with fainting (ectopic alert), soaking >2 pads/hour for 2 hours, or foul discharge/malaise >24 hours after Misoprostol.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.15] (p. 162)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.